Joe Hargrove, MD
Cardiovascular Disease · Little Rock, ARNPI 1285628065
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,914 of the $3,130 with a category attached, or 61.1%. Novartis accounts for 76.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $1,356 and has fallen 98.9% since, to $15 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in AR, where the typical reported total is $3,368.
Across 28 payments — averaging $111.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Astellas Pharma US Inc$283
- Abbott$201
- Biotronik Inc.$120
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$53
- Boehringer Ingelheim$45
- plus $41 from 3 others
Across 62 payments — averaging $8417.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$253K
- Eli Lilly$65K
- Astrazeneca UK Limited$65K
- AstraZeneca$49K
- Vertex$35K
- Amgen$20K
- plus $36K from 6 others
What the payments were for
- Travel & lodging$1,91461%
- Food & beverage$93330%
- Education$2839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 9 | $2,387 |
| Astellas Pharma US Inc | 3 | $283 |
| Abbott | 2 | $201 |
| Biotronik Inc. | 2 | $120 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $53 |
| Boehringer Ingelheim | 2 | $45 |
| Boston Scientific | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MitraClip System$104
How this compares
$3,130 in reported general payments places this provider in the 45th percentile of 130 cardiovascular disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 377 | $292,964 |
| EntrestoSacubitril/Valsartan | 169 | $169,502 |
| JardianceEmpagliflozin | 208 | $168,087 |
| XareltoRivaroxaban | 59 | $59,229 |
| FarxigaDapagliflozin Propanediol | 43 | $27,685 |
| MultaqDronedarone Hcl | 14 | $10,922 |
| Ranolazine ErRanolazine | 70 | $7,304 |
| CorlanorIvabradine Hcl | 11 | $6,747 |
| Atorvastatin Calcium | 549 | $4,273 |
| Amlodipine Besylate | 695 | $3,738 |
| Rosuvastatin Calcium | 322 | $3,689 |
| Metoprolol Succinate | 354 | $3,194 |
| Metoprolol Tartrate | 596 | $2,994 |
| Losartan Potassium | 369 | $2,715 |
| Potassium Chloride | 144 | $2,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $2,387 | $169,502169 claims |
| Boehringer IngelheimJardiance | $45 | $168,087208 claims |
| Johnson & JohnsonXarelto | $14 | $59,22959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 130 cardiovascular disease providers in Arkansas.
Other cardiovascular disease in Little Rock
- Ian CawichLittle Rock$294K
- William RollefsonLittle Rock$74K
- Andre PaixaoLittle Rock$73K
- Wesley LaneLittle Rock$46K
- Omar QaqishLittle Rock$45K
- Barry UretskyLittle Rock$36K
- Freddy ChrismanLittle Rock$26K
- Forrest GloverLittle Rock$17K
- Clayton BorgLittle Rock$14K
- David MegoLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.